Chronic Lyme disease: it's not all in our heads. by Morgenstern, Robert G
Chronic Lyme Disease:
Psychogenic Fantasy or
Somatic Infection?
Sigal and Hassett published an article about
Lyme disease in the EHP Supplements
(Sigal and Hassett 2002), suggesting that
chronic Lyme disease is “psychogenic.” I
do not think that Sigal and Hassett, non-
psychiatrists, are qualified to speak about
psychiatric matters. I, however, actually
have had the disease, which they character-
ize as “medically unexplained,” for over 25
years and have 15 years of experience as a
patient advocate and educator. I beg to
differ.
Many reports in the peer-reviewed med-
ical literature substantiate the notion of per-
sistent infection. Borrelia burgdorferi, the
causative organism, has been cultured after
“adequate” antibiotic therapy from the
brain, eye, heart, spleen, spinal fluid, skin,
lymph nodes, joints, and synovial fluid
(Cimmino et al. 1989; Cimperman et al.
1996; Haupl et al. 1993; Liegner et al.
1992; Oksi et al. 1996; Patmas 1994; Peter
et al. 1993; Pfister et al. 1991; Preac Mursic
et al. 1993; Reimers et al. 1993; Schmidli et
al. 1988). Table 1 provides information on
some of the articles supporting persistent
infection. A more complete listing of Lyme
disease abstracts may be obtained from the
Lyme Disease Network (2002).
I and the many other Lyme patients I
know are neither “confused” nor “inse-
cure.“ We did not seek a “societally and
morally acceptable explanation” (Sigal and
Hassett 2002) for our illness; we sought a
scientific and medical explanation. We have
been fortunate enough to find informed
doctors to treat us with long-term antibi-
otics and to return to our normal activities.
In my experience, patients with Lyme dis-
ease who are treated for psychogenic ill-
nesses alone do not fare well. 
Phyllis Mervine
Lyme Disease Resource Center
Ukiah, California
E-mail: pmerv@direcway.com
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Table 1. Available information of Lyme disease.
Reference Summary
Battafarano et al. 1993  “A patient had chronic septic Lyme arthritis of the knee for 7 years, despite multiple antibiotic trials and multiple arthroscopic and open 
synovectomies. Spirochetes were documented in synovium and synovial fluid.”
Cimmino et al. 1989 “G-penicillin treatment was ineffective.… Borrelia-like spirochetes were identified histologically in the spleen.”
Georgilis et al. 1992 “Fibroblasts protected B. burgdorferi for at least 14 days of exposure to ceftriaxone.” Other cell types also protected B. burgdorferi, 
contributing to its long-term survival.
Haupl et al. 1993 The patient had relapsing Lyme borreliosis with choroiditis, arthritis, carditis, and tendinitis. Repeated antibiotic treatment was necessary 
to stop the progression of disease but did not completely eliminate B. burgdorferi from all sites of infection. Viable B. burgdorferi was 
cultured from a ligament sample obtained surgically. 
Liegner et al. 1992 Paired CSF and serum tests for antibodies to B. burgdorferi and PCR for B. burgdorferi-specific oligonucleotides in CSF were negative. 
Eleven months later, after treatment with cefotaxime and minocycline, a T-cell stimulation test with B. burgdorferi antigens was strongly 
positive. A year later, paired serum and CSF samples were strongly positive for antibodies to B. burgdorferi and CSF was culture positive.
Liegner et al. 1993 Patient was ELISA-negative after treatment, but blood was PCR-positive and B. burgdorferi-compatible structure was visualized in skin 
biopsy. Further treatment resolved erythema migrans. 
Montgomery et al. 1993 “The macrophage is a known reservoir for a number of infectious agents, and is therefore a likely candidate site for persistence of 
Borrelia burgdorferi …. Although the large majority of spirochetes within a given cell were dead, we saw occasional live ones … and can 
reculture [them].”
Oksi et al. 1999 One patient had been treated for 47 weeks, including 7 weeks of intravenous ceftriaxone; primary diagnosis was confirmed by positive
biopsy and the relapse 44 weeks after treatment confirmed by a positive plasma PCR. One patient had relapse 130 weeks after 
16 weeks of treatment. The patient was seropositive initially but seronegative at relapse. Relapse was confirmed by positive PCR, and 
there was no history of reinfection. 
Preac Mursic et al. 1996 Persistence of B. burgdorferi s.l. and clinical recurrences occur in patients despite antibiotic treatment. Culture confirmed relapses after 
12–14 days of treatment courses in five patients.
Straubinger et al. 1997 “Treatment with high doses of amoxicillin or doxycycline for 30 days diminished but failed to eliminate persistent infection.” Antibody 
titers fell, but 6 months after antibiotic treatment was discontinued, “antibody levels began to rise again, presumably in response to 
proliferation of the surviving pool of spirochetes.”
Abbreviations: CSF, cerebrospinal fluid; PCR, polymerase chain reaction.Chronic Lyme Disease: It’s Not
All in Our Heads 
Those of us with chronic Lyme disease are
not at all confused, as suggested by Sigal and
Hassett (2002). We know from years of
experience that we have real, specific symp-
toms that are usually painful and disabling
and include severe headaches, crippling
arthritis, and heart palpitations, which lead
to serious heart disease. Many of us know
that our symptoms are kept in check while
we are on antibiotics, but they painfully
reappear when the antibiotics are with-
drawn. Just because the medical community
cannot detect a specific causative bacterium
and managed health care companies want to
maximize profits doesn’t mean that those of
us afflicted with this terrible condition are
delusional and not truly benefiting from
antibiotic treatment. We are not all crazy;
we are sick and we should not be required to
prove it to get medical care. 
Robert G. Morgenstern 
Brooklyn, New York
E-mail: Bob2221M@aol.com
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Chronic Lyme Disease: Sigal
and Hassett’s Response
Nowhere in our article (Sigal and Hassett
2002) do we minimize or devalue the pain
or suffering of patients with chronic Lyme
disease nor do we state that such patients
are “crazy” or “delusional.” Further, we do
not dismiss the possibility that some such
patients actually have infection that persists
despite adequate prior antibiotic treatment.
Nonetheless, we take this opportunity to
again issue a caution against making the
diagnosis of chronic Lyme disease in the
absence of objective clinical and microbio-
logic evidence of infection. 
Without demonstrable physical findings
and laboratory proof of the persistence of
Borrelia burgdorferi, the diagnosis should
remain in significant doubt. Certainly, a
few, often poorly documented case reports
claiming persistence (many in Europe,
where the organism, the vector, and the
ambient human immunogenetic types are
different) cannot be a basis for the wide-
spread diagnosis of chronic infection in cer-
tain regions of the United States and in
certain practices. 
We hope our article (Sigal and Hassett
2002) will help educate physicians and assist
them in being more sensitive to their patients
and to more correctly identify the true
underlying cause of their patients’ symptoms
in a compassionate manner. However, many
patients are misdiagnosed with chronic Lyme
disease, a diagnosis often made to provide an
explanation for a bewildering array of com-
plaints within an acceptable framework for
both patient and physician. Instead, these
patients deserve the truth. Improvement and
cure require provision of a correct scientific
and medical explanation and properly
directed therapies. For many of the patients
we see, chronic antibiotics, continuous reas-
surance, and yet another antibiotic regimen
when the current one fails have led to frus-
tration, anger, depression, and chronic suf-
fering. Further, the inappropriate use of
broad spectrum antibiotics, often for long
periods, is not without personal (e.g.,
Clostridium dificile infection, allergies, and
other adverse reactions) and societal (e.g.,
contribution to the development of resistant
strains such as methicillin- and vancomycin-
resistant Staphylococcus) risks. 
Leonard H. Sigal
Afton L. Hassett
UMDNJ-Robert Wood Johnson 
Medical School
New Brunswick,New Jersey
E-mail: sigallh@umdnj.edu
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Cancer in Beluga from the St.
Lawrence Estuary 
Martineau et al. (2002) reported that St.
Lawrence beluga (SLB) have high cancer
rates. Unfortunately, errors in their inter-
pretation of the data have led them to over-
state the importance of cancer and its links
to environmental sources.
Martineau et al. (2002) compared mor-
tality patterns between the beach-cast, natu-
rally dead animals in the protected,
predation-free SLB population with those
from a hunted Alaskan beluga population,
which were also subject to natural predation
(Burns and Seaman 1985). This analysis is
incorrect because it compares the raw fre-
quency distribution of ages at death of SLB
with an age structure reconstructed by fitting
a model to the Alaskan age and reproductive
data from the harvest, under the assumption
of constant natural mortality (Burns and
Seaman 1985). A correct analysis (Burns and
Seaman 1985) of the SLB data shows that
mortality rises continuously from about
6 years of age. There is no peak in the 20s,
and no difference in standing population at
21–25 years of age between Alaskan beluga
[8%: Table 7 in (Burns and Seaman 1985)]
and SLB [8.1%: stranding data 1982–1998
(Martineau et al. 2002)]. 
Martineau et al. (2002) estimated an
annual cancer rate (AR) among SLB beluga
using
where t is 17 years. The authors used an aer-
ial survey index estimate of 650 whales,
which incorporates a conservative 15% cor-
rection factor to account for animals that
were below the surface on transect lines and
therefore unseen (Kingsley 1999). Our con-
cern is the author’s failure to recognize the
importance of this correction to their con-
clusions. Kingsley (1999) applied a factor of
2.09, developed specifically for SLB
(Kinglsey and Gauthier. In Press), to the
average of five surveys using similar methods
between 1988 and 1997, and hence esti-
mated a mean fully corrected population
size of 1,100 ± 113 (mean ± SD) whales.
Using this estimate of population size
reduces the cancer rate from 163 to 96
(95% confidence interval, 88–105).
Martineau et al. (2002) asserted that the
rate of winter stranding is as high as or
higher than that during the rest of the year
because of harsh weather conditions, but
that these carcasses are not recovered and
adjust their calculations accordingly. These
adjustments may be inappropriate for two
reasons. First, the beluga is an Arctic species
adapted to ice and cold water, and is
unlikely to be stressed by winter conditions
in the St. Lawrence; mortality rates could in
fact be lower during this period. Second,
animals that die in winter could freeze into
the ice and be beach-cast and thus recovered
after breakup. A more appropriate estimated
minimum with cancer (EMC) can be esti-
mated from the observed stranding rate as a
minimum, resulting in an EMC of 47, or as
one end of a range of 47–63. The adjusted
estimated annual rate (AAR) of cancer for a
complete year, 
would then be 251 instead of the value of
570 presented by Martineau (2002). The
AAR of cancer in SLB is then no longer the
highest of the seven species they tabulated.
Martineau et al. (2002) argued that epi-
demiologically the SLB data resemble
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animals because population size is known;
however, they then cited incorrect popula-
tion estimates for the SLB. They also stated
that rates among pets are overestimated
because pets are protected from other causes
of death. Cancer rates in pets are not over-
estimated; they are high because death is
inevitable, and mortality from predation,
trauma, and malnutrition is nearly non-
existent—just as is the case for the SLB.
The absence of malnutrition as a cause
of death and the generally good body con-
dition of recovered carcasses from this
unhunted, predator-free, wild population is
unusual. The small number of juvenile car-
casses recovered, prima facie indicates a bias
toward older adults, whereas the absence of
emaciated carcasses may indicate a bias
against animals in poor condition that are
likely to sink. The beach-cast sample of car-
casses is clearly incomplete and must be
assumed to be biased. The direction and
size of this bias is unknown, but it may
increase the apparent significance of cancer.
Martineau et al. (2002) suggested that
bottom invertebrates from the sediments of
the Saguenay Fjord are important in the
diet, and a significant source of contamina-
tion with polycyclic aromatic hydrocarbons
(PAHs), leading to high cancer rates.
However, the Saguenay River is not used
extensively by all SLB, particularly west of
the Baie Ste. Marguerite area, for which
PAH data are available. Furthermore, the
only existing diet data come not from the
Saguenay, but from collections made else-
where in the St. Lawrence over 60 years ago
(Vladykov 1946).
The SLB population is unique in its
accessibility and in its geographic isolation
from Arctic conspecifics. The incidence of
cancer among a sample of beach-cast animals
is interesting, but failure to make the proper
links between a sample with unknown bias
and the population means that the impor-
tance of cancer in this population and links
to environmental conditions are overstated.
Mike O. Hammill
Véronique Lesage
Department of Fisheries and Oceans Canada
Mont Joli, Quebec, Canada
E-mail: Hammillm@dfo-mpo.gc.ca
Michael C.S. Kingsley
Greenland Institute of Natural Resources,
Nuuk, Greenland
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Cancer in Beluga: Response
In their letter, Hammill et al. propose an
analysis of mortality patterns for the St.
Lawrence beluga (SLB) population without
submitting data or methods. They state,
however, that there is no difference in stand-
ing populations at 21–25  years of age
between Alaskan beluga and SLB, support-
ing our conclusion that the high cancer rate
in this age group cannot be explained by its
overrepresentation in the SLB population
(Martineau et al. 2002a). We have also
shown in an earlier paper (Béland et al.
1988) and in an updated analysis (Béland et
al. Unpublished data) that SLB do not die at
a more advanced age than Arctic beluga.
Hammill et al. suggest that the SLB popula-
tion, the denominator used in estimating
cancer rate, is larger than the value we used
and thus the resulting cancer rate would be
lower than that we obtained (Martineau et
al. 2002b). We used 650, the population
estimate that was both undisputed and pub-
lished in a refereed scientific journal at that
time (and still is) (Lesage and Kingsley
1998). Hammill et al. use a higher, recently
developed correction factor of 2.09 to esti-
mate the mean population size at 1,100.
Importantly, Kingsley, a coauthor of the let-
ter, previously stated that the mortality rate
we used elsewhere, 1.4%, was unrealistically
low (Kingsley 2002)—with which we con-
curred (Martineau 2002). Using a higher,
more realistic annual 6% death rate from a
population of 960, Kingsley (2002) esti-
mated the SLB mortality rate at 58
deaths/year and derived an adjusted esti-
mated annual rate (AAR) of 1,208, more
than twice the AAR we estimated. (Using a
population estimate of 1,100, he would have
obtained an even higher AAR of 1,433.)
Our record includes emaciated individ-
uals, a large number of young animals
[22.4% of strandings were ≤ 6 years old
(Béland et al. 1988)], and very few beach-
cast animals that died over the winter. We
assumed that the number of stranding
occurring during winter is at least the same
as that reported during the rest of the year
(Martineau et al. 2002b). It is difficult to
conceive that the ice cover and rough
weather conditions which prevail in winter
would lower mortality rates in animals that
need to surface regularly for breathing,
especially considering that SLB are often
affected by pneumonia (Martineau et al.
1994). In addition, “carcasses with terminal
diseases are often found after several days of
rough weather” (Martineau et al. 2002b).
Predation-induced mortality would muddle
the issue, but predation seems not to be an
important cause of mortality, as stated by
Hammill et al. 
Because the populations of pets used to
determine cancer rates were exclusively ani-
mals examined in veterinary hospitals
(Martineau et al 2002b; Priester and
Mantel 1971; Priester and McKay 1980),
many of these animals, if not most, were
sick; thus, cancer rates are more frequent in
these animals than in the general popula-
tion of domestic animals—the same way
that cancer patients are proportionally more
numerous in a hospital than they are in the
general human population (Priester and
McKay 1980; Priester and Mantel 1971).
In addition, most pet animals are sheltered
and receive veterinary curative and preven-
tive care along with abundant well-balanced
food. Because cancer develops more fre-
quently in older animals and humans, these
factors, by prolonging life span, increase
cancer rates relatively to free-ranging ani-
mals (Martineau et al 2002b; Fowler 1987). 
The Saguenay River has been qualified as
“extensively used” by SLB (Michaud 1993).
SLB are grouped in three types of herds:
adults and juveniles, only adults, and mixed
herds. Among seven areas qualified as “exten-
sively used” by SLB, the Saguenay River is
one of only two areas frequented a substan-
tial amount of time by the three types of
herds. In addition, 5% of the population, on
average, is found in the Saguenay River in the
summer (Michaud 1993; Environnement
Canada 1995). SLB are present in the
Saguenay River, occasionally up to 100 km
upstream, in the segment most contami-
nated by polycyclic aromatic hydrocarbons
(PAHs) (Martel et al. 1986, 1987; Michaud
1993). Sainte-Marguerite Bay, located 24
km upstream the Saguenay River, is fre-
quented daily by groups of SLB remaining
in the bay up to 16 hr, probably for feeding
(Michaud 1993). Benthic invertebrates are
part of the diet of SLB, and benthic inverte-
brates are present in the Saguenay River
(Lemieux 1996; Vladykov 1946). There is
no reason to believe that SLB actively avoid
these prey in the Saguenay River. 
Mussels at the mouth of the Saguenay
River accumulated PAHs produced by the
local aluminum smelters, and clean mussels
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lated benzo[a]pyrene concentrations that
were 200 times higher than pretransplanta-
tion concentrations, demonstrating that
PAHs are also being exported into the St
Lawrence Estuary (Cossa et al. 1983; Picard-
Bérubé and Cossa 1983). 
In conclusion, irrespective of uncertain-
ties regarding population size, the percentage
of mortality in SLB due to cancer is very high
relative to other free-ranging mammals and
to free-ranging cetaceans [for instance 2 of 90
dolphins (Cowan DF. Personal communica-
tion)] examined in similar conditions, and is
higher than in pets and in humans [Figure 4
in Martineau et al 2002b] (Cowan et al.
1986; Howard et al. 1983; Kirkwood et al.
1997; Kuiken et al. 1993; Stroud and Roffe
1979). The contamination of the Saguenay
River and immediate St. Lawrence estuary
area by PAHs released massively by the local
aluminum smelters over half a century and
the exposure of belugas to these compounds
make PAHs the most likely etiology for cer-
tain types of cancer in SLB as we stated in
our article (Martineau et al. 2002b).
Daniel Martineau
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Pascal Michel
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Correspondence
Correction
In the editorial in the January issue of
EHP [111:A14–A15 (2003)], David
Michaels was described as the first recipi-
ent of the American Public Health
Association’s David P. Rall Award for
Advocacy in Public Health; he was actually
the second recipient of the award. Eula
Bingham received the first David P. Rall
Award in 2000.
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